HSD3B1 Genotyping for Personalized Corticosteroid Response in Asthma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current asthma treatments rely on subjective symptoms and uniform therapeutic approaches, leading to under- and over-treatment due to the lack of personalized medicine strategies based on underlying mechanisms, and there is a need for non-invasive biomarkers to identify responder endotypes for therapies like anti-IgE and anti-IL5.
Innovation Solution
Methods and kits for testing HSD3B1 gene variants and 3β-HSD1 protein expression to determine if a subject should be administered corticosteroids or non-corticosteroids, specifically using genetic and protein assays to identify A/A, A/C, or C/C genotypes and 367N or 367T protein versions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If uniform stepped-care approach is used for all asthma patients, then treatment simplicity is maintained, but treatment precision and personalization deteriorate
Solution Approach 1:
The patent segments the homogeneous asthma patient population into distinct endotype groups based on HSD3B1 genotype (A/A, A/C, C/C) and 3β-HSD1 protein expression levels. This segmentation enables personalized treatment recommendations by identifying specific molecular characteristics that predict corticosteroid responsiveness, thereby resolving the contradiction between treatment simplicity and precision.
2Measurement precision
If genetic and protein testing is implemented, then treatment personalization is improved, but diagnostic complexity increases
Solution Approach 1:
The patent extracts and focuses on specific, clinically actionable biomarkers (HSD3B1 gene variants at position 1245 and 3β-HSD1 protein expression) from the complex genomic and proteomic landscape. By concentrating on these particular markers rather than进行全面 genomic analysis, the patent reduces diagnostic complexity while maintaining treatment personalization benefits.
Solution Approach 2:
The patent performs preliminary genotyping and protein expression assessment to classify patients into endotypes before initiating or adjusting corticosteroid therapy. This preliminary action guides treatment selection in advance, avoiding the need for complex trial-and-error adjustments during treatment and simplifying the overall diagnostic-therapeutic workflow.
3Quantity of substance
If corticosteroid treatment is applied uniformly, then treatment coverage is maximized, but treatment efficacy deteriorates due to non-responders
Solution Approach 1:
The patent implements a feedback mechanism where HSD3B1 genotype and 3β-HSD1 protein expression results directly inform corticosteroid treatment decisions. Patients with molecular profiles indicating corticosteroid non-responsiveness (e.g., A/A or A/C genotypes with low 3β-HSD1 expression) are identified and directed toward alternative therapies, thereby improving overall treatment efficacy while maintaining appropriate coverage through targeted alternative interventions.
Data Source
AI summary
The present invention relates to methods, kits, and compositions for testing a sample from a subject with asthma to determine: i) if the subject is A/A or A/C at position 1245 in the HSD3B1 gene, and/or if the subject expresses a 367N version of the 3β-HSD1 protein (e.g., and should be administered a non-corticosteroid for their asthma), or ii) if the subject is C/C at position 1245 in the HSD3B1 gene, and/or if the subject expresses only the 367T version of the 3β-HSD1 protein (e.g., and should be administered a corticosteroid for their asthma). In certain embodiments, the corticosteroid is a glucocorticoid.